Reizdarmsyndrom – eine Krankheit

[1]  W. Chey,et al.  Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use , 2017, The American Journal of Gastroenterology.

[2]  P. Whorwell,et al.  New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline , 2017, Expert review of gastroenterology & hepatology.

[3]  R. Gearry,et al.  Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date , 2016, Clinical and experimental gastroenterology.

[4]  E. Zoetendal,et al.  The Intestinal Microenvironment and Functional Gastrointestinal Disorders. , 2016, Gastroenterology.

[5]  B. Löwe,et al.  Post-infectious irritable bowel syndrome (PI-IBS) after infection with Shiga-like toxin-producing Escherichia coli (STEC) O104:H4: A cohort study with prospective follow-up , 2016, United European gastroenterology journal.

[6]  P. Whorwell,et al.  Hypnotherapy for irritable bowel syndrome: an audit of one thousand adult patients , 2015, Alimentary pharmacology & therapeutics.

[7]  P. Moayyedi,et al.  Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis , 2014, The American Journal of Gastroenterology.

[8]  P. Moayyedi,et al.  Effect of Antidepressants and Psychological Therapies, Including Hypnotherapy, in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis , 2014, The American Journal of Gastroenterology.

[9]  Y. Falck‐Ytter,et al.  Effect of linaclotide in irritable bowel syndrome with constipation (IBS‐C): a systematic review and meta‐analysis , 2014, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[10]  I. Hall,et al.  A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea , 2013, Gut.

[11]  N. D. de Wit,et al.  Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. , 2011, The Cochrane database of systematic reviews.

[12]  P. Enck,et al.  [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. , 2011, Zeitschrift fur Gastroenterologie.

[13]  M. Camilleri,et al.  Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  Y. Katayama.  Bowel disorders. , 1990, Postgraduate medicine.